Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc. FUSN Peers
See (FUSN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FUSN | $21.55 | +0.14% | 1.83B | -15.39 | -$1.40 | N/A |
| VRTX | $434.03 | -0.30% | 111.46B | -113.32 | -$3.83 | N/A |
| REGN | $596.79 | -1.30% | 63.35B | 15.16 | $39.36 | +0.30% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $289.00 | -1.22% | 37.68B | -137.62 | -$2.10 | N/A |
| ARGX | $581.44 | -0.60% | 35.50B | 35.41 | $16.42 | N/A |
| BNTX | $99.07 | -0.02% | 23.82B | -27.60 | -$3.59 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| SMMT | $25.77 | +1.42% | 19.01B | -75.79 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
Stock Comparison
FUSN vs VRTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, VRTX has a market cap of 111.46B. Regarding current trading prices, FUSN is priced at $21.55, while VRTX trades at $434.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas VRTX's P/E ratio is -113.32. In terms of profitability, FUSN's ROE is -0.49%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, FUSN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs REGN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, REGN has a market cap of 63.35B. Regarding current trading prices, FUSN is priced at $21.55, while REGN trades at $596.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas REGN's P/E ratio is 15.16. In terms of profitability, FUSN's ROE is -0.49%, compared to REGN's ROE of +0.15%. Regarding short-term risk, FUSN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs SGEN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, FUSN is priced at $21.55, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, FUSN's ROE is -0.49%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, FUSN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs ALNY Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ALNY has a market cap of 37.68B. Regarding current trading prices, FUSN is priced at $21.55, while ALNY trades at $289.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ALNY's P/E ratio is -137.62. In terms of profitability, FUSN's ROE is -0.49%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, FUSN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ARGX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ARGX has a market cap of 35.50B. Regarding current trading prices, FUSN is priced at $21.55, while ARGX trades at $581.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ARGX's P/E ratio is 35.41. In terms of profitability, FUSN's ROE is -0.49%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, FUSN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BNTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BNTX has a market cap of 23.82B. Regarding current trading prices, FUSN is priced at $21.55, while BNTX trades at $99.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BNTX's P/E ratio is -27.60. In terms of profitability, FUSN's ROE is -0.49%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, FUSN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BGNE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, FUSN is priced at $21.55, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, FUSN's ROE is -0.49%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, FUSN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs SMMT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SMMT has a market cap of 19.01B. Regarding current trading prices, FUSN is priced at $21.55, while SMMT trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SMMT's P/E ratio is -75.79. In terms of profitability, FUSN's ROE is -0.49%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, FUSN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs DNA-WT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, FUSN is priced at $21.55, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, FUSN's ROE is -0.49%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, FUSN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RPRX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RPRX has a market cap of 18.16B. Regarding current trading prices, FUSN is priced at $21.55, while RPRX trades at $32.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RPRX's P/E ratio is 13.19. In terms of profitability, FUSN's ROE is -0.49%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, FUSN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs UTHR Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, UTHR has a market cap of 13.93B. Regarding current trading prices, FUSN is priced at $21.55, while UTHR trades at $308.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas UTHR's P/E ratio is 12.29. In terms of profitability, FUSN's ROE is -0.49%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, FUSN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs GMAB Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, GMAB has a market cap of 13.15B. Regarding current trading prices, FUSN is priced at $21.55, while GMAB trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas GMAB's P/E ratio is 12.37. In terms of profitability, FUSN's ROE is -0.49%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, FUSN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs KRTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, FUSN is priced at $21.55, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, FUSN's ROE is -0.49%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, FUSN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs INCY Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, INCY has a market cap of 12.49B. Regarding current trading prices, FUSN is priced at $21.55, while INCY trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas INCY's P/E ratio is 322.55. In terms of profitability, FUSN's ROE is -0.49%, compared to INCY's ROE of +0.01%. Regarding short-term risk, FUSN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs EXEL Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, EXEL has a market cap of 11.69B. Regarding current trading prices, FUSN is priced at $21.55, while EXEL trades at $42.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas EXEL's P/E ratio is 19.57. In terms of profitability, FUSN's ROE is -0.49%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, FUSN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BMRN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BMRN has a market cap of 11.12B. Regarding current trading prices, FUSN is priced at $21.55, while BMRN trades at $58.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BMRN's P/E ratio is 21.49. In terms of profitability, FUSN's ROE is -0.49%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, FUSN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MRNA Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MRNA has a market cap of 10.33B. Regarding current trading prices, FUSN is priced at $21.55, while MRNA trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MRNA's P/E ratio is -3.06. In terms of profitability, FUSN's ROE is -0.49%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, FUSN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ASND Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ASND has a market cap of 9.66B. Regarding current trading prices, FUSN is priced at $21.55, while ASND trades at $160.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ASND's P/E ratio is -24.51. In terms of profitability, FUSN's ROE is -0.49%, compared to ASND's ROE of +1.91%. Regarding short-term risk, FUSN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RXDX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, FUSN is priced at $21.55, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, FUSN's ROE is -0.49%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, FUSN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs IMGN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, FUSN is priced at $21.55, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, FUSN's ROE is -0.49%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, FUSN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs CERE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, FUSN is priced at $21.55, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, FUSN's ROE is -0.49%, compared to CERE's ROE of -0.99%. Regarding short-term risk, FUSN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs CORT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CORT has a market cap of 8.07B. Regarding current trading prices, FUSN is priced at $21.55, while CORT trades at $76.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CORT's P/E ratio is 66.17. In terms of profitability, FUSN's ROE is -0.49%, compared to CORT's ROE of +0.20%. Regarding short-term risk, FUSN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ROIVW Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, FUSN is priced at $21.55, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, FUSN's ROE is -0.49%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, FUSN is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ROIV Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ROIV has a market cap of 7.81B. Regarding current trading prices, FUSN is priced at $21.55, while ROIV trades at $10.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ROIV's P/E ratio is -10.94. In terms of profitability, FUSN's ROE is -0.49%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, FUSN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs TECH Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, TECH has a market cap of 7.42B. Regarding current trading prices, FUSN is priced at $21.55, while TECH trades at $47.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas TECH's P/E ratio is 57.01. In terms of profitability, FUSN's ROE is -0.49%, compared to TECH's ROE of +0.06%. Regarding short-term risk, FUSN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RVMD Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RVMD has a market cap of 7.23B. Regarding current trading prices, FUSN is priced at $21.55, while RVMD trades at $38.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RVMD's P/E ratio is -9.68. In terms of profitability, FUSN's ROE is -0.49%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, FUSN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs JAZZ Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, JAZZ has a market cap of 6.64B. Regarding current trading prices, FUSN is priced at $21.55, while JAZZ trades at $107.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas JAZZ's P/E ratio is 14.65. In terms of profitability, FUSN's ROE is -0.49%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, FUSN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs HALO Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, HALO has a market cap of 6.62B. Regarding current trading prices, FUSN is priced at $21.55, while HALO trades at $53.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas HALO's P/E ratio is 14.30. In terms of profitability, FUSN's ROE is -0.49%, compared to HALO's ROE of +1.22%. Regarding short-term risk, FUSN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RETA Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, FUSN is priced at $21.55, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, FUSN's ROE is -0.49%, compared to RETA's ROE of +0.47%. Regarding short-term risk, FUSN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs BPMC Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BPMC has a market cap of 6.48B. Regarding current trading prices, FUSN is priced at $21.55, while BPMC trades at $100.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BPMC's P/E ratio is -39.98. In terms of profitability, FUSN's ROE is -0.49%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, FUSN is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BBIO Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BBIO has a market cap of 6.26B. Regarding current trading prices, FUSN is priced at $21.55, while BBIO trades at $32.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BBIO's P/E ratio is -9.26. In terms of profitability, FUSN's ROE is -0.49%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, FUSN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs VRNA Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, VRNA has a market cap of 6.18B. Regarding current trading prices, FUSN is priced at $21.55, while VRNA trades at $72.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas VRNA's P/E ratio is -36.34. In terms of profitability, FUSN's ROE is -0.49%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, FUSN is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MDGL Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MDGL has a market cap of 6.07B. Regarding current trading prices, FUSN is priced at $21.55, while MDGL trades at $273.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MDGL's P/E ratio is -15.33. In terms of profitability, FUSN's ROE is -0.49%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, FUSN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ABCM Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, FUSN is priced at $21.55, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, FUSN's ROE is -0.49%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, FUSN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs ISEE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, FUSN is priced at $21.55, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, FUSN's ROE is -0.49%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, FUSN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs TGTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, TGTX has a market cap of 5.44B. Regarding current trading prices, FUSN is priced at $21.55, while TGTX trades at $34.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas TGTX's P/E ratio is 136.96. In terms of profitability, FUSN's ROE is -0.49%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, FUSN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs TLX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, TLX has a market cap of 5.42B. Regarding current trading prices, FUSN is priced at $21.55, while TLX trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas TLX's P/E ratio is 180.00. In terms of profitability, FUSN's ROE is -0.49%, compared to TLX's ROE of +0.14%. Regarding short-term risk, FUSN is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs IONS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, IONS has a market cap of 5.29B. Regarding current trading prices, FUSN is priced at $21.55, while IONS trades at $33.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas IONS's P/E ratio is -11.12. In terms of profitability, FUSN's ROE is -0.49%, compared to IONS's ROE of -0.00%. Regarding short-term risk, FUSN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs NUVL Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, NUVL has a market cap of 5.26B. Regarding current trading prices, FUSN is priced at $21.55, while NUVL trades at $73.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas NUVL's P/E ratio is -16.58. In terms of profitability, FUSN's ROE is -0.49%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, FUSN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs AXSM Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, AXSM has a market cap of 5.14B. Regarding current trading prices, FUSN is priced at $21.55, while AXSM trades at $104.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas AXSM's P/E ratio is -18.05. In terms of profitability, FUSN's ROE is -0.49%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, FUSN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ALKS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ALKS has a market cap of 4.96B. Regarding current trading prices, FUSN is priced at $21.55, while ALKS trades at $30.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ALKS's P/E ratio is 14.31. In terms of profitability, FUSN's ROE is -0.49%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, FUSN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ADMA Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ADMA has a market cap of 4.81B. Regarding current trading prices, FUSN is priced at $21.55, while ADMA trades at $20.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ADMA's P/E ratio is 24.00. In terms of profitability, FUSN's ROE is -0.49%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, FUSN is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ALPN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, FUSN is priced at $21.55, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, FUSN's ROE is -0.49%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, FUSN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs PCVX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, PCVX has a market cap of 4.38B. Regarding current trading prices, FUSN is priced at $21.55, while PCVX trades at $33.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas PCVX's P/E ratio is -8.51. In terms of profitability, FUSN's ROE is -0.49%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, FUSN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs OPT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, FUSN is priced at $21.55, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, FUSN's ROE is -0.49%, compared to OPT's ROE of +2.60%. Regarding short-term risk, FUSN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs MRTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, FUSN is priced at $21.55, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, FUSN's ROE is -0.49%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, FUSN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RYTM Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RYTM has a market cap of 3.95B. Regarding current trading prices, FUSN is priced at $21.55, while RYTM trades at $62.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RYTM's P/E ratio is -22.15. In terms of profitability, FUSN's ROE is -0.49%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, FUSN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs AKRO Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, AKRO has a market cap of 3.90B. Regarding current trading prices, FUSN is priced at $21.55, while AKRO trades at $48.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas AKRO's P/E ratio is -13.06. In terms of profitability, FUSN's ROE is -0.49%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, FUSN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs SRPT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SRPT has a market cap of 3.81B. Regarding current trading prices, FUSN is priced at $21.55, while SRPT trades at $38.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SRPT's P/E ratio is -14.69. In terms of profitability, FUSN's ROE is -0.49%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, FUSN is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RYZB Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, FUSN is priced at $21.55, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, FUSN's ROE is -0.49%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, FUSN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs CBAY Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, FUSN is priced at $21.55, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, FUSN's ROE is -0.49%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, FUSN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs SLNO Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SLNO has a market cap of 3.72B. Regarding current trading prices, FUSN is priced at $21.55, while SLNO trades at $73.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SLNO's P/E ratio is -15.59. In terms of profitability, FUSN's ROE is -0.49%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, FUSN is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs RNA Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RNA has a market cap of 3.71B. Regarding current trading prices, FUSN is priced at $21.55, while RNA trades at $30.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RNA's P/E ratio is -10.27. In terms of profitability, FUSN's ROE is -0.49%, compared to RNA's ROE of -0.27%. Regarding short-term risk, FUSN is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CYTK Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CYTK has a market cap of 3.64B. Regarding current trading prices, FUSN is priced at $21.55, while CYTK trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CYTK's P/E ratio is -5.76. In terms of profitability, FUSN's ROE is -0.49%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, FUSN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs KRYS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, KRYS has a market cap of 3.62B. Regarding current trading prices, FUSN is priced at $21.55, while KRYS trades at $125.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas KRYS's P/E ratio is 30.05. In terms of profitability, FUSN's ROE is -0.49%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, FUSN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs PTCT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, PTCT has a market cap of 3.61B. Regarding current trading prices, FUSN is priced at $21.55, while PTCT trades at $45.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas PTCT's P/E ratio is 6.99. In terms of profitability, FUSN's ROE is -0.49%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, FUSN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ACAD Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ACAD has a market cap of 3.61B. Regarding current trading prices, FUSN is priced at $21.55, while ACAD trades at $21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ACAD's P/E ratio is 15.73. In terms of profitability, FUSN's ROE is -0.49%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, FUSN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ACLX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ACLX has a market cap of 3.59B. Regarding current trading prices, FUSN is priced at $21.55, while ACLX trades at $65.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ACLX's P/E ratio is -21.81. In terms of profitability, FUSN's ROE is -0.49%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, FUSN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs SWTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SWTX has a market cap of 3.49B. Regarding current trading prices, FUSN is priced at $21.55, while SWTX trades at $46.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SWTX's P/E ratio is -13.57. In terms of profitability, FUSN's ROE is -0.49%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, FUSN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs RARE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, RARE has a market cap of 3.36B. Regarding current trading prices, FUSN is priced at $21.55, while RARE trades at $35.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas RARE's P/E ratio is -6.09. In terms of profitability, FUSN's ROE is -0.49%, compared to RARE's ROE of -1.86%. Regarding short-term risk, FUSN is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CRSP Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CRSP has a market cap of 3.24B. Regarding current trading prices, FUSN is priced at $21.55, while CRSP trades at $37.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CRSP's P/E ratio is -8.36. In terms of profitability, FUSN's ROE is -0.49%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, FUSN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs VKTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, VKTX has a market cap of 3.11B. Regarding current trading prices, FUSN is priced at $21.55, while VKTX trades at $27.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas VKTX's P/E ratio is -23.91. In terms of profitability, FUSN's ROE is -0.49%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, FUSN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MTSR Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MTSR has a market cap of 2.95B. Regarding current trading prices, FUSN is priced at $21.55, while MTSR trades at $28.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MTSR's P/E ratio is -11.04. In terms of profitability, FUSN's ROE is -0.49%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, FUSN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CPRX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CPRX has a market cap of 2.94B. Regarding current trading prices, FUSN is priced at $21.55, while CPRX trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CPRX's P/E ratio is 15.36. In terms of profitability, FUSN's ROE is -0.49%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, FUSN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs SRRK Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, SRRK has a market cap of 2.89B. Regarding current trading prices, FUSN is priced at $21.55, while SRRK trades at $30.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas SRRK's P/E ratio is -11.95. In terms of profitability, FUSN's ROE is -0.49%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, FUSN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MRUS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MRUS has a market cap of 2.88B. Regarding current trading prices, FUSN is priced at $21.55, while MRUS trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MRUS's P/E ratio is -10.00. In terms of profitability, FUSN's ROE is -0.49%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, FUSN is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MORF Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, FUSN is priced at $21.55, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MORF's P/E ratio is -14.88. In terms of profitability, FUSN's ROE is -0.49%, compared to MORF's ROE of -0.27%. Regarding short-term risk, FUSN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs MOR Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, FUSN is priced at $21.55, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MOR's P/E ratio is -12.64. In terms of profitability, FUSN's ROE is -0.49%, compared to MOR's ROE of +7.43%. Regarding short-term risk, FUSN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs PTGX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, PTGX has a market cap of 2.85B. Regarding current trading prices, FUSN is priced at $21.55, while PTGX trades at $45.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas PTGX's P/E ratio is 58.86. In terms of profitability, FUSN's ROE is -0.49%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, FUSN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CRNX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CRNX has a market cap of 2.82B. Regarding current trading prices, FUSN is priced at $21.55, while CRNX trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CRNX's P/E ratio is -7.92. In terms of profitability, FUSN's ROE is -0.49%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, FUSN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs KDNY Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, FUSN is priced at $21.55, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas KDNY's P/E ratio is -12.47. In terms of profitability, FUSN's ROE is -0.49%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, FUSN is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs LEGN Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, LEGN has a market cap of 2.67B. Regarding current trading prices, FUSN is priced at $21.55, while LEGN trades at $29.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas LEGN's P/E ratio is -24.62. In terms of profitability, FUSN's ROE is -0.49%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, FUSN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MYOV Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, FUSN is priced at $21.55, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MYOV's P/E ratio is -14.05. In terms of profitability, FUSN's ROE is -0.49%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, FUSN is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs IMVT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, IMVT has a market cap of 2.47B. Regarding current trading prices, FUSN is priced at $21.55, while IMVT trades at $14.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas IMVT's P/E ratio is -5.56. In terms of profitability, FUSN's ROE is -0.49%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, FUSN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MLTX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MLTX has a market cap of 2.44B. Regarding current trading prices, FUSN is priced at $21.55, while MLTX trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MLTX's P/E ratio is -16.74. In terms of profitability, FUSN's ROE is -0.49%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, FUSN is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs APGE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, APGE has a market cap of 2.40B. Regarding current trading prices, FUSN is priced at $21.55, while APGE trades at $40.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas APGE's P/E ratio is -11.18. In terms of profitability, FUSN's ROE is -0.49%, compared to APGE's ROE of -0.19%. Regarding short-term risk, FUSN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs PRVB Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, FUSN is priced at $21.55, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas PRVB's P/E ratio is -16.43. In terms of profitability, FUSN's ROE is -0.49%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, FUSN is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs IBRX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, IBRX has a market cap of 2.37B. Regarding current trading prices, FUSN is priced at $21.55, while IBRX trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas IBRX's P/E ratio is -4.70. In terms of profitability, FUSN's ROE is -0.49%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, FUSN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs LBPH Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, FUSN is priced at $21.55, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas LBPH's P/E ratio is -26.66. In terms of profitability, FUSN's ROE is -0.49%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, FUSN is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for FUSN.
FUSN vs XENE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, XENE has a market cap of 2.34B. Regarding current trading prices, FUSN is priced at $21.55, while XENE trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas XENE's P/E ratio is -9.47. In terms of profitability, FUSN's ROE is -0.49%, compared to XENE's ROE of -0.32%. Regarding short-term risk, FUSN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs DICE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, FUSN is priced at $21.55, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas DICE's P/E ratio is -21.91. In terms of profitability, FUSN's ROE is -0.49%, compared to DICE's ROE of +0.56%. Regarding short-term risk, FUSN is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs APLS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, APLS has a market cap of 2.23B. Regarding current trading prices, FUSN is priced at $21.55, while APLS trades at $17.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas APLS's P/E ratio is -9.88. In terms of profitability, FUSN's ROE is -0.49%, compared to APLS's ROE of -1.00%. Regarding short-term risk, FUSN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs AAPG Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, AAPG has a market cap of 2.20B. Regarding current trading prices, FUSN is priced at $21.55, while AAPG trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas AAPG's P/E ratio is -34.31. In terms of profitability, FUSN's ROE is -0.49%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, FUSN is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs MIRM Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, MIRM has a market cap of 2.18B. Regarding current trading prices, FUSN is priced at $21.55, while MIRM trades at $44.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas MIRM's P/E ratio is -27.36. In terms of profitability, FUSN's ROE is -0.49%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, FUSN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BCRX Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BCRX has a market cap of 2.17B. Regarding current trading prices, FUSN is priced at $21.55, while BCRX trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BCRX's P/E ratio is -39.96. In terms of profitability, FUSN's ROE is -0.49%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, FUSN is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CALT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, FUSN is priced at $21.55, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CALT's P/E ratio is -22.73. In terms of profitability, FUSN's ROE is -0.49%, compared to CALT's ROE of -2.10%. Regarding short-term risk, FUSN is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs VCYT Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, VCYT has a market cap of 2.15B. Regarding current trading prices, FUSN is priced at $21.55, while VCYT trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas VCYT's P/E ratio is 65.24. In terms of profitability, FUSN's ROE is -0.49%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, FUSN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs ARWR Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, ARWR has a market cap of 2.13B. Regarding current trading prices, FUSN is priced at $21.55, while ARWR trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas ARWR's P/E ratio is -12.41. In terms of profitability, FUSN's ROE is -0.49%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, FUSN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs BLTE Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, BLTE has a market cap of 2.10B. Regarding current trading prices, FUSN is priced at $21.55, while BLTE trades at $64.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas BLTE's P/E ratio is -47.52. In terms of profitability, FUSN's ROE is -0.49%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, FUSN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs VCEL Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, VCEL has a market cap of 2.08B. Regarding current trading prices, FUSN is priced at $21.55, while VCEL trades at $41.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas VCEL's P/E ratio is 827.60. In terms of profitability, FUSN's ROE is -0.49%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, FUSN is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs NAMS Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, NAMS has a market cap of 2.05B. Regarding current trading prices, FUSN is priced at $21.55, while NAMS trades at $18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas NAMS's P/E ratio is -9.93. In terms of profitability, FUSN's ROE is -0.49%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, FUSN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs DNLI Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, DNLI has a market cap of 1.98B. Regarding current trading prices, FUSN is priced at $21.55, while DNLI trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas DNLI's P/E ratio is -5.12. In terms of profitability, FUSN's ROE is -0.49%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, FUSN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs KYMR Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, KYMR has a market cap of 1.96B. Regarding current trading prices, FUSN is priced at $21.55, while KYMR trades at $30.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas KYMR's P/E ratio is -9.70. In terms of profitability, FUSN's ROE is -0.49%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, FUSN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs NAMSW Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, NAMSW has a market cap of 1.96B. Regarding current trading prices, FUSN is priced at $21.55, while NAMSW trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas NAMSW's P/E ratio is N/A. In terms of profitability, FUSN's ROE is -0.49%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, FUSN is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs CGON Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, CGON has a market cap of 1.96B. Regarding current trading prices, FUSN is priced at $21.55, while CGON trades at $25.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas CGON's P/E ratio is -17.17. In terms of profitability, FUSN's ROE is -0.49%, compared to CGON's ROE of -0.11%. Regarding short-term risk, FUSN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs HRMY Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, HRMY has a market cap of 1.96B. Regarding current trading prices, FUSN is priced at $21.55, while HRMY trades at $34.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas HRMY's P/E ratio is 13.03. In terms of profitability, FUSN's ROE is -0.49%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, FUSN is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs LGND Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, LGND has a market cap of 1.95B. Regarding current trading prices, FUSN is priced at $21.55, while LGND trades at $101.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas LGND's P/E ratio is -13.89. In terms of profitability, FUSN's ROE is -0.49%, compared to LGND's ROE of -0.16%. Regarding short-term risk, FUSN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs FOLD Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, FOLD has a market cap of 1.93B. Regarding current trading prices, FUSN is priced at $21.55, while FOLD trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas FOLD's P/E ratio is -69.56. In terms of profitability, FUSN's ROE is -0.49%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, FUSN is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.
FUSN vs GLPG Comparison
FUSN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FUSN stands at 1.83B. In comparison, GLPG has a market cap of 1.90B. Regarding current trading prices, FUSN is priced at $21.55, while GLPG trades at $28.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FUSN currently has a P/E ratio of -15.39, whereas GLPG's P/E ratio is -9.37. In terms of profitability, FUSN's ROE is -0.49%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, FUSN is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for FUSN.